COMMUNIQUÉS West-GlobeNewswire

Optinose Provides Corporate Update on XHANCE Launch and Outlook and Announces Preliminary First Quarter 2024 XHANCE Net Revenue of $14.9 million

25/04/2024 - 13:00

Conference Call and Webcast to be held April 25, 2024, at 10:00 a.m. Eastern Time YARDLEY, Pa., April 25, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, [...]

BioXcel Therapeutics to Report First Quarter 2024 Financial Results on May 9, 2024

25/04/2024 - 13:00

NEW HAVEN, Conn., April 25, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and [...]

Nucleome Therapeutics appoints Dr John Davis as Non-Executive Director of the Board and establishes Scientific Advisory Board of world-leading experts

25/04/2024 - 13:00

Nucleome Therapeutics appoints Dr John Davis as Non-Executive Director of the Board and establishes Scientific Advisory Board of world-leading experts John Davis brings direct clinical expertise as Nucleome advances [...]

Regeneron and Mammoth Biosciences Collaborate to Pursue Next-Generation CRISPR-Based Gene Editing for Multiple Diseases

25/04/2024 - 13:00

Mammoth’s proprietary ultracompact CRISPR-based gene editing platform and Regeneron’s proprietary delivery technologies set to advance in vivo programs in multiple tissue and cell types Mammoth to receive $100 million [...]

Microbix Collaborator Introduces New Lab Accreditation Program

25/04/2024 - 13:00

Microbix Product Supporting Testing for Drug-Resistant Sexually-Transmitted Infection MISSISSAUGA, Ontario, April 25, 2024 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. ( TSX: MBX, OTCQX: MBXBF, Microbix ® ), a life [...]

TELA Bio to Announce First Quarter 2024 Financial Results

25/04/2024 - 13:00

MALVERN, Pa., April 25, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today [...]

Morphic Announces Corporate Highlights and Financial Results for the First Quarter 2024

25/04/2024 - 13:00

- Enrollment continued on target in EMERALD-2 Phase 2b trial of MORF-057 in ulcerative colitis- -Appointed Dr. Simon Cooper as Chief Medical Officer- -Anticipate dosing first patient in GARNET Phase 2 study of MORF-057 [...]

Kymera Therapeutics to Report First Quarter 2024 Financial Results on May 2

25/04/2024 - 13:00

WATERTOWN, Mass., April 25, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein [...]

Parexel and Palantir Expand Collaboration to Accelerate Clinical Data Delivery and Power Clinical Outcomes for Patients

25/04/2024 - 12:59

DURHAM, N.C. and DENVER, April 25, 2024 (GLOBE NEWSWIRE) -- Parexel, one of the world’s largest clinical research organizations (CROs) providing the full range of Phase I to IV clinical development services, and [...]

Nexstim Plc: Managers’ Transactions, Hildén

25/04/2024 - 12:15

Company Announcement, Helsinki, 25 April 2024 at 1:15 PM (EEST) Nexstim Plc: Managers’ Transactions, Hildén Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") announces managers’ transactions as follows: Person subject to [...]

Nexstim Plc: Managers’ Transactions, Forss

25/04/2024 - 12:10

Company Announcement, Helsinki, 25 April 2024 at 1:10 PM (EEST) Nexstim Plc: Managers’ Transactions, Forss Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") announces managers’ transactions as follows: Person subject to [...]

Nexstim Plc: Managers’ Transactions, Weckroth

25/04/2024 - 12:05

Company Announcement, Helsinki, 25 April 2024 at 1:05 PM (EEST) Nexstim Plc: Managers’ Transactions, Weckroth Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") announces managers’ transactions as follows: Person subject [...]

MEDIROM Healthcare Technologies Inc. Announces March 2024 Key Performance Indicators (KPIs)

25/04/2024 - 12:01

Total Customers Served: 77,854 – Sales Per Customer: JPY 7,190 – Customer Repeat Ratio: 77.9% TOKYO, April 25, 2024 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (NasdaqCM: MRM), a holistic healthcare company [...]

eyeDNA Therapeutics to Present 2-year Follow-up Phase I/II Data on its Investigational Gene Therapy HORA-PDE6b for Retinitis Pigmentosa at the ARVO 2024 Annual Meeting

25/04/2024 - 12:00

Paris, France, April 25, 2024 – eyeDNA Therapeutics (‘eyeDNA’), a newly created subsidiary of Coave Therapeutics (‘Coave’), a genetic medicine company focused on developing life-changing therapies, announces that [...]

Nexstim Plc: Managers’ Transactions, Niemistö

25/04/2024 - 12:00

Company Announcement, Helsinki, 25 April 2024 at 1 PM (EEST) Nexstim Plc: Managers’ Transactions, Niemistö Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") announces managers’ transactions as follows: Person subject to [...]

Enterome to Present Clinical Data on EO2463 in B-cell Lymphoma at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

25/04/2024 - 12:00

Poster presentation to highlight updated data from ongoing Phase 1/2 of EO2463 monotherapy and in combination with lenalidomide and/or rituximab in indolent non-Hodgkin lymphoma (NHL) PARIS, April 25, 2024 (GLOBE [...]

Orion Group Interim Report January–March 2024

25/04/2024 - 11:00

ORION CORPORATION INTERIM REPORT 1-3/2024 25 APRIL 2024 at 12:00 EEST Orion Group Interim Report January–March 2024 Net sales totalled EUR 308.5 (January–March 2023: 277.9) million Operating profit was EUR 56.0 (55.5) [...]

PEP-Therapy and Institut Curie Announce First Patients Dosed in Phase Ib Clinical Trial Evaluating PEP-010 in Ovarian and Pancreatic Cancers

25/04/2024 - 11:00

Press release PEP-Therapy and Institut Curie Announce First Patients Dosed in Phase Ib Clinical Trial Evaluating PEP-010 in Ovarian and Pancreatic Cancers Paris (France), April 25, 2024 – PEP-Therapy, a clinical-stage [...]

PEP-Therapy et l’Institut Curie annoncent le traitement des premiers patients dans la phase Ib de l’essai clinique évaluant PEP-010 dans les cancers de l’ovaire et du pancréas

25/04/2024 - 11:00

Communiqué de presse PEP-Therapy et l’Institut Curie annoncent le traitement des premiers patients dans la phase Ib de l’essai clinique évaluant PEP-010 dans les cancers de l’ovaire et du pancréas Paris (France), le 25 [...]